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Objectives. High morbidity of elective inguinofemoral lymphadenectomy in early stage vulvar cancer patients urges the need for defining a
group of low-risk patients in whom inguinofemoral lymphadenectomy can be safely omitted. Aim of the study was to evaluate whether in addition
to ‘classic’ clinicopathological factors determination of EGFR expression in vulvar cancer can be helpful in defining such a ‘low-risk’ group.
Methods. Formalin-fixed paraffin-embedded tumor tissue samples of 197 surgically treated T1/2 patients were collected in a Tissue Micro
Array (TMA). On this TMA, immunohistochemistry for EGFR was performed. Logistic regression analyses were performed including
histopathological characteristics with the presence of nodal metastases as outcome. A predictive model was constructed, and absolute risks were
calculated.
Results. EGFR expression was present in 68% of the vulvar tumors and related to the presence of lymph node metastases (OR 2.12, 95% CI
1.09–4.10). Our predictive model with only clinicopathological factors was able to define a group of patients with a likelihood of absence of
lymph node metastases of 13% (95% CI 5–36), which could be decreased to 6% (95% CI 0–29) after inclusion of EGFR expression (p=0.07).
Conclusions. EGFR expression is present in the majority of vulvar tumors and is associated with groin node metastases in vulvar cancer.
Current classic clinicopathological predictive factors for inguinofemoral lymph node metastases with or without EGFR analysis are not strong
enough for identification of “sufficiently low” risk T1/2 vulvar cancer patients. Our predictive model approach however is excellent for evaluation
of new cell biological parameters, associated with clinical outcome.
© 2006 Published by Elsevier Inc.Keywords: Vulvar cancer; Lymphatic metastases; Epidermal growth factor receptorIntroduction
Carcinoma of the vulva is a rare disease which predomi-
nantly affects elderly women. The most common histological
type is squamous cell carcinoma which accounts for 90% of all
vulvar carcinomas [1]. Standard treatment for squamous cell
carcinoma of the vulva is wide local excision with elective uni-
or bilateral superficial and deep inguinofemoral lymphadenec-⁎ Corresponding author. Fax: +31 50 3611806.
E-mail address: a.g.j.van.der.zee@og.umcg.nl (A.G.J. van der Zee).
0090-8258/$ - see front matter © 2006 Published by Elsevier Inc.
doi:10.1016/j.ygyno.2006.07.035tomy via separate incisions. Although effective with respect to
cure, the morbidity of this treatment is high and especially
related to the lymphadenectomy with frequent wound break-
down, infections, and lymphedema of the legs as major
complications [2,3].
About 20–30% of patients with early stage squamous cell
carcinoma of the vulva (T1 (≤2 cm) or T2 (>2 cm) tumor,
without suspicious groins) will have inguinofemoral lymph
node metastases. In retrospect, 70–80% of these patients will
therefore probably not benefit from complete inguinofemoral
lymphadenectomy but are at risk for its major complications.
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lymph node metastases may have major impact for the patients
because of the high mortality associated with groin recurrences,
especially in an undissected groin [4]. In the light of these
considerations, gynecologic oncologists throughout the world
regard an elective inguinofemoral lymphadenectomy as stan-
dard of care in early stage vulvar cancer patients with depth of
invasion >1 mm.
To obviate the morbidity of elective inguinofemoral
lymphadenectomy, while maintaining a very low number of
groin recurrences, the demands for non- or minimally
invasive techniques for exclusion of inguinofemoral lymph
node metastases are extremely high. In a recent review [5], it
was shown that currently available non-invasive diagnostic
tests (palpation, ultrasound (with or without FNA cytology),
CT, MRI, PET) are not able to exclude inguinofemoral lymph
node metastases with a certainty that is high enough to safely
omit complete inguinofemoral lymphadenectomy, while the
safety of the sentinel node technique is currently being
evaluated in phase II studies [6–8]. Studies on different
histopathogical parameters of the primary vulvar tumor
showed a very low (<1%) risk for inguinofemoral metastases
in tumors with a depth of invasion less than 1 mm [9–13]. No
other ‘classic’ histopathological parameters are able to define
comparable “low-risk groups” of patients with invasive
squamous cell carcinoma of the vulva. In addition, a variety
of cell biological parameters, more or less associated with
metastatic behavior of the primary tumor, have been evaluated
for their predictive value, but overall these data are
inconclusive and conflicting, especially because the number
of patients analyzed in these studies is often too small.
So far, the only parameter with potentially high enough
negative predictive value to exclude lymph node metastases
in patients with vulvar carcinoma was the absence of
epidermal growth factor receptor (EGFR) overexpression.
EGFR activation plays a key role in cell adhesion, cell
locomotion, cell survival, invasion, and angiogenesis, which
results in modulation of tumor progression, e.g. metastases
[14].
In this study, we analyzed the relation between expression
of EGFR with inguinofemoral lymph node metastases in a
large group of patients with early stage squamous cell
carcinoma of the vulva. As the focus for the clinician is to
find a way to avoid an elective inguinofemoral lymphade-
nectomy, we then constructed a predictive model including
classic clinicopathological and immunostaining parameters to
identify a group of patients with a low likelihood of presence
of inguinofemoral lymph node metastases.
Patients and methods
Patients
Since 1984, clinicopathological and follow-up data of all patients referred
to the Department of Gynecologic Oncology of the University Medical Center
Groningen, The Netherlands are prospectively collected during standard
treatment and follow-up and stored in a computerized registration database,
which is managed in accordance with the hospitals regulations. For thecurrent study, all consecutive squamous cell vulvar cancer patients with T1–2
tumors treated from March 1984 until January 2000 were selected. Patients
who did not undergo inguinofemoral lymphadenectomy were excluded
(n=25); 7 because of FIGO stage IA disease and 18 because of bad general
health. Until 1993, standard treatment consisted of radical vulvectomy with
en bloc uni- or bilateral inguinofemoral lymphadenectomy. Since 1993, this
treatment was modified to wide local excision with uni- or bilateral
inguinofemoral lymphadenectomy via separate incisions. Staging was
performed according to the surgicopathologic FIGO classification [15] and
the AJCC TNM classification [16].
IRB approval
For the present study, all relevant data were retrieved from our previously
mentioned, larger, computerized database into a separate, anonymous
database. In this separate, password protected database, patient identity was
protected by study-specific, unique patient numbers, which codes were only
known to two dedicated datamanagers, who also have daily responsibility for
the larger database. In case of uncertainties with respect to clinicopathologic
and follow-up data, the larger databases could only be checked through the
datamanagers, thereby ascertaining the protection of patients' identity. Due to
these procedures according to Dutch law, no further patient or IRB approval
was needed.
Histology
Results of the histological diagnosis of the biopsy and surgical specimen
were taken together. Biopsies examined at regional pathology laboratories were
requested for review. The tumors were examined for tumor thickness, degree of
differentiation, vascular invasion, and multifocality. Using a calibrated eyepiece
micrometer, tumor thickness was measured from the tumor surface or, in the
case of superficial keratosis, from the level of the stratum granulosum downward
to the deepest point of the tumor; the thickness of the keratin layer, if present,
was therefore neglected. The degree of differentiation in the most prominent part
of the tumor was assessed according to the criteria described elsewhere [17].
Capillary-lymphatic infiltration was defined as the presence of tumor emboli in
endothelial-lined spaces. The inguinofemoral lymph nodes from each side were
examined (one section per cm node) for the presence of intranodal or extranodal
metastatic tumor growth.
Immunohistochemistry
Formalin-fixed paraffin-embedded tumor tissue samples from all patients
were available for constructing Tissue Micro Arrays (TMAs). Morphologically
representative areas of the primary tumor were marked on hematoxylin- and
eosin-stained sections. Areas of necrosis or severe leukocyte infiltration were
avoided. Three cores of 0.6 mm in diameter were taken from the marked areas
out of the corresponding tissue block and were placed in pre-defined array
locations in a recipient blank paraffin block, using a precision instrument
(Beecher Instruments, Silver Spring, Maryland). After inserting the cores, the
blocks were placed in an oven of 37°C for 30 min in order to attach the cores
to the surrounding paraffin. In total, three arrays were constructed, each
containing three cores per tumor. Cores of histologically normal vulvar tissue
and vulvar cancer tissue originating from the same donor blocks were
incorporated in all three arrays to serve as internal control for intra-run
variability and to help to orientate oneself in the TMA. Sections of 4 μm were
cut from the arrays and were transferred to adhesive coated slides.
Immunohistochemistry for EGFR was performed on these TMAs with
primary mouse anti-human EGFR monoclonal antibody (clone 31G7,
Zymed, #28-005). Slides were cleared in xylene and rehydrated through a
graded ethanol series in distilled water. They were subjected to antigen
retrieval using a 0.1% Trypsin (0.1% Calcium Chloride) solution at 37°C for
10 min. Immunostaining was performed using the DAKO autostainer.
Diaminobenzidine (DAB) was used as chromogen to visualize the antibody.
The nuclei were counterstained in Mayer's hematoxylin, dehydrated in graded
ethanol, dried and coverslipped. For EGFR staining, sections from an ovarian
cancer specimen with well established EGFR overexpression were used as
Table 1
Patient and disease characteristics related to the EGFR (n (%); χ2 test; p value)
Characteristics EGFR (moderate/strong) positive χ2 test
Age
Under age 73 59 (60.2) χ2=4.75
73 and over 74 (74.7) p=0.03
T-status
T1 (maximum diameter ≤2 cm) 27 (58.7) χ2=2.13
T2 (maximum diameter >2 cm) 106 (70.2) p=0.15
Depth of infiltration
≤5 mm 42 (54.5) χ2=10.3
>5 mm 91 (76.5) p=0.001
Grade of differentiation
Good 51 (65.4)
Moderate 69 (75.8) χ2=8.70
Poor 13 (46.4) p=0.01
Vascular invasion
No 111 (65.7) χ2=1.82
Yes 54 (78.6) p=0.18
Table 2
Patient and disease characteristics total and related to the presence of nodal









Under age 73 98 (49.7) 32 (45.1) 1




46 (23.4) 9 (12.7) 1
T2 (maximum
diameter >2 cm)
151 (76.6) 62 (87.3) 2.86 (1.29–6.36)
Depth of infiltration a
≤5 mm 77 (39.1) 17 (23.9) 1
>5 mm 119 (60.4) 54 (76.1) 2.93 (1.53–5.61)
Grade of differentiation
Good 78 (39.6) 20 (28.2) 1
Moderate 91 (46.2) 36 (50.7) 1.90 (0.98–3.67)
Poor 28 (14.2) 15 (21.1) 3.35 (1.36–8.23)
Vascular invasion
No 169 (85.8) 58 (81.7) 1
Yes 28 (14.2) 13 (18.3) 1.66 (0.74–3.72)
EGFR
Negative 64 (32.5) 16 (22.5) 1
(Moderate/strong) positive 133 (67.5) 55 (77.5) 2.12 (1.09–4.10)
a Could not be assessed for one patient.
111M.H.M. Oonk et al. / Gynecologic Oncology 104 (2007) 109–113positive controls. Isotype IgG antibodies replacing the primary antibody
served as negative control.
The staining intensity for EGFR observed in each core was scored on a four-
point scale for EGFR (0=negative, 1=weakly positive, 2=positive, 3=strongly
positive). Scoring was independently performed by two of the authors (KA ten
Hoor andDJ van der Veen), and a concordance of more than 95%was found. The
discordant cases were reviewed, and scores were reassigned on consensus of
opinion. For our statistical analyses, we used the average intensity score of three
cores.
Statistics
Statistical analysis was carried out using Statistical Package for the Social
Sciences (SPSS) version 12.01. To determine whether single predictive factors
differed significantly between patients with and without nodal metastasis at the
moment of diagnosis, odds ratios were estimated by univariate logistic
regression with the presence of nodal metastases as dependent variable. Then,
a multivariate logistic regression analysis was performed with again the
presence of nodal metastasis as dependent variable, including the variables that
contributed statistically significantly in the univariate analysis. Based on this,
two predictive models were constructed: one with only classic predictive
factors, and one with inclusion of EGFR. The values of the β-coefficients of
the variables included in the multivariate logistic regression equation were
used to generate two scoring formulas, one including classic predictive factors
and one including classic predictive factors as well as EGFR. The predicted
probability for the presence of nodal metastases in both models was calculated
for each patient. In the following, it was verified how many subjects were
identified correctly by using different cut off values of the scoring formulas.
The observed values according to the value of the scoring formulas were
grouped, and the observed numbers of patients in total as well as the observed
numbers of patients with nodal metastasis were counted. All tests were two-
sided and P values of <0.05 were considered significant.
Results
Patients
Between March 1984 and January 2000, 197 patients with
primary T1 or T2 squamous cell tumors of the vulva were
surgically treated at the University Medical Center Groningen,The Netherlands. Median age was 73 years (range: 34–94).
Forty-six (23.4%) patients had a T1 tumor and 151 (76.6%) a T2
tumor. The primary vulvar tumor was unilateral in 111 patients
(56.3%) and bilateral in 85 patients (43.2%) (one missing value).
Multifocality of the primary tumor was seen in 30 patients
(15.2%). One or more inguinofemoral lymph node metastases
were present in 71/197 patients (36%). Thirty patients had one
positive inguinofemoral lymph node, 19 patients two, and 11
patients three or more positive inguinofemoral lymph nodes.
Follow-up data were available for all patients and have been
published previously [18], but are not further reported here.
Immunostaining
Positive staining for EGFR was observed in 68% of the
tumors. Positive staining for EGFR was associated with a depth
of invasion >5 mm (p=0.001) and with good to moderate grade
of differentiation (p=0.01). There was no relation with age,
T-status and vascular invasion. Chi-square tests for EGFR
staining in relation to different tumor characteristics are shown
in Table 1.
Clinicopathological and immunostaining parameters in
relation to inguinofemoral lymph node metastases
For an overview of patient and tumor characteristics related
to the presence of lymph node metastases and the univariate
Table 3
Patient and disease characteristics related to the presence of nodal metastasis
(n=71) at the moment of diagnosis of primary tumor: a model excluding and a
model including EGFR (multivariate OR, 95% CI)




1.81 (0.76–4.30) 1.75 (0.73–4.20)
Depth of infiltration
>5 mm 2.53 (1.25–5.01) 2.26 (1.09–4.62)
Grade of differentiation
Moderate 1.81 (0.91–3.60) 1.75 (0.88–3.50)
Poor 3.33 (1.30–8.53) 3.94 (1.48–10.51)
EGFR
Positive – 1.95 (0.93–4.08)
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2.86, 95% CI 1.29–6.36), depth of infiltration (OR 2.93, 95%
CI 1.53–5.61), grade of differentiation (good versus poor: OR
3.35, 95% CI 1.36–8.23), and EGFR status (OR 2.12, 95% CI
1.09–4.10) were all associated with the presence of lymph
node metastases. The two multivariate logistic regression
models, one with and one without EGFR, are shown in
Table 3. EGFR did not retain its predictive value in the
multivariate analysis. EGFR staining intensity was positive
(moderate–strong) in 78/126 (61.9%) of the patients without
nodal metastases and in 55/71 (77.5%) of the patients with
nodal metastases (OR: 2.1, 95% CI: 1.1–4.1).
A predictive model for inguinofemoral lymph node metastases
The values of the β-coefficients of the tumor characteristics
included in the multivariate logistic regression equation were
used in the predictive models shown in Tables 3 (without
EGFR) and 4 (with EGFR). Our predictive model based on
clinicopathological parameters without EGFR allowed identi-
fication of T1/2 patients with a likelihood of absence of lymph
node metastases of 13% (95% CI 5–36; 30 (15%) patients),
which could be decreased to 6% (95% CI 0–29) afterTable 4
Number of patients with different score levels (divided into four groups) in relation to
primary tumor










0–2 16 6 (38%) 0.12–0.7
2–4 78 40 (51%) 0.38–0.6
4–6 48 33 (69%) 0.53–0.8
6–8 37 30 (81%) 0.64–0.9
8–9 17 16 (94%) 0.71–1.0
a Score=1.75 (if T1-status is present)+2.25 (if depth of infiltration ≤5 mm)+
differentiation is present)+1.95 (if EGFR is negative).
b Score=1.81 (if T1-status is present)+2.53 (if depth of infiltration ≤5 mm)+
differentiation is present).inclusion of EGFR expression (p=0.07; 17 (9%) patients)
(Table 4).
Discussion
Our study shows that EGFR expression is present in the
majority of primary squamous cell carcinomas of the vulva and
that it is associated with the presence of inguinofemoral lymph
node metastases. However, it has no value in the prediction of
lymph node metastases.
So far, expression of EGFR in vulvar cancer has been
evaluated only to a very limited extent. Berchuck et al.
showed in 34 squamous carcinomas of the cervix, vulva and
vagina that EGFR expression was moderate to heavy in all
malignant cells [19]. Another small study on EGFR
expression in vulvar cancer showed progressive increase in
EGFR expression from benign vulvar epithelial to primary
malignant tissue to metastatic lesions within the same patient.
Increased expression of EFGR in the primary vulvar tumor
was also significantly associated with lymph node metastases,
but its predictive value was not properly addressed [14].
Studies on EGFR expression in other gynecologic malig-
nancies showed that EGFR overexpression is associated with
biological aggressiveness and poor prognosis in cervical
cancer [20–22]. Multivariate analysis of risk factors for
metastatic disease showed that EGFR overexpression in
endometrial cancer is an independent predictor for the
presence of metastases [23].
Regarding primary squamous cell carcinoma of the vulva,
there is a wealth of studies reporting associations between a
variety of cell biological parameters and patients characte-
ristics such as presence of lymph node metastases. However,
most of these studies give the decision-maker no indication of
the absolute number of people who might benefit from adding
these biological parameters to routine diagnostics. In the
presented study here, after calculating the relative risks for the
absence of groin node metastases in vulvar cancer, the
absolute risks were calculated for the absence of these
metastases. Based on these absolute risks, we were able tothe probability of the absence of nodal metastases at the moment of diagnosis of










0 67 33 (49%) 0.36–0.61
0 55 32 (58%) 0.43–0.70
2 44 34 (77%) 0.62–0.88
0 30 26 (87%) 0.64–0.95
0 –
3.94 (if good grade of differentiation is present)+2.26 (if moderate grade of
3.33 (if good grade of differentiation is present)+1.84 (if moderate grade of
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associated with inguinofemoral lymph node metastases, its
expression analysis allows us to define only a small group of
patients (9%) with a likelihood of absence of lymph node
metastases of still 6% with a relatively wide 95% CI (0–29).
These figures would implicate a false-negative rate for
prediction of inguinofemoral lymph node metastases of at
least 6%.
The high morbidity of elective inguinofemoral lymphade-
nectomy in early stage vulvar cancer patients urges the need
for defining a group of ‘low-risk’ patients in whom
inguinofemoral lymphadenectomy can be safely omitted.
When debating a possible acceptable false-negative rate for
sentinel node detection in vulvar cancer the Gynecologic
Oncology Group of the European Organisation for Research
and Treatment of Cancer (EORTC) decided that in the light of
the significant decrease in morbidity by omitting elective
lymphadenectomy a maximum increase of groin recurrences
(i.e. a false-negative rate) of 6% might be acceptable. Our
study showed that based on the currently available clinico-
pathological data with or without inclusion of EGFR
expression analysis we could not identify accurately a cohort
of T1/2 patients with such a low likelihood of inguinofemoral
lymph node metastases. The upper level of our 95% CI was
higher than the required 6%. The predictive model approach
that we used for the present study however seems to be quite
feasible for the evaluation of the predictive value of future
cell biological parameters possibly associated with metastatic
behavior.
Currently, no non-invasive technique is available for
accurate prediction of inguinofemoral lymph node status. At
present, the sentinel node technique seems to be the most
promising minimal-invasive technique for defining a group of
vulvar cancer patients in whom inguinofemoral lymphadenect-
omy can be safely omitted. Further research is required in order
to find more powerful predictive markers for inguinofemoral
lymph node metastases. Our predictive model and the
availability of TMAs of early stage vulvar cancer will allow
rapid and accurate evaluation of these new markers.
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